Murine mesothelin: Characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer

Journal of Experimental and Clinical Cancer Research

Volumn 35, Issue 1, 2016, Pages

  Zervos, Emmanuel ^a   Agle, Steven ^a   Freistaedter, Andrew G ^a   Jones, Gwendolyn J B ^a   Roper, Rachel L ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Immune; Mesothelin; Pancreas; Proliferation; Tumor

Indexed keywords

MESOTHELIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SEQUENCE ANALYSIS; TISSUE DISTRIBUTION; ANIMAL; CONSERVED SEQUENCE; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CONSERVED SEQUENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HEK293 CELLS; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS;

EID: 84978704312     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-016-0314-2     Document Type: Article

References (33)

1. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-8.
2. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol. 2005;13:243-7.
3. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008;7:286-96.
4. Ho M, Bera TK, Willingham MC, et al. Mesothelin expression in human lung cancer. Clin Cancer Res. 2007;13:1571-5.
5. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000;20:2902-6.
6. Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014;20(4):1020.
7. Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012;18(9):2478-89.
8. Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, Fleisher M, Rusch VW, Adusumilli PS. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012;21(3):482-6.
9. Imamura O, Okada H, Takashima Y, Zhang D, Kobayashi T, Hino O. siRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model. Cancer Lett. 2008;268:278-85.
10. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190-8.
11. Chang CL, Wu TC, Hung CF. Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther. 2007;14:1189-98.
12. Chowdhury PS, Pastan I. Analysis of cloned Fvs from a phage display library indicates that DNA immunization can mimic antibody response generated by cell immunizations. J Immunol Methods. 1999;231:83-91.
13. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106:3360-5.
14. Yokokawa J, Palena C, Arlen P, et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res. 2005;11:6342-51.
15. Kelly RJ, Sharon E, Pastan I, et al. Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development. Mol Cancer Ther. 2012;11:517-25.
16. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8 (+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200:297-306.
17. Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20.
18. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-26.
19. Group USCSW. United States Cancer Statistics: 2008-2012 Incidence and Mortality Web-based Report. 2015 [cited Sept 14, 2015]; Available from: https://nccd.cdc.gov/uscs/toptencancers.aspx.
20. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992;52:881-6.
21. Nakaishi M, Kajino K, Ikesue M, et al. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin. Cancer Sci. 2007;98:659-64.
22. Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev. 2006;15:1751.
23. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447-53.
24. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-28.
25. Hagiwara Y, Hamada Y, Kuwahara M, et al. Establishment of a novel specific ELISA system for rat N-and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma. Cancer Sci. 2008;99:666-70.
26. Zhang D, Kobayashi T, Kojima T, et al. Deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 knockout mice. Cancer Sci. 2011.
27. Zheng C, Jia W, Tang Y, et al. Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and independent signal pathway. J Exp Clin Can Res. 2012;31:84.
28. Zhang S, Yong L-K, Li D, et al. Mesothelin Virus-Like Particle Immunization Controls Pancreatic Cancer Growth through CD8+ T cell Induction and Reduction in Frequency of CD4 + foxp3 + ICOS-Regulatory T cells. PLoS One. 2013;8, e68303.
29. Pastan I, Hassan R. Discovery of Mesothelin and Exploiting it as a Target for Immunotherapy. Cancer Res. 2014;74:2907-12.
30. Luo M, Brooks M, Wicha MS. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des. 2015;21(10):1301-10.
31. Pietila M, Ivaska J, Mani SA. Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment? Cancer Lett. 2016 Jan 11.
32. Ye LY, Chen W, Bai XL, et al. Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. Cancer Res. 2016;76:818-30.
33. Brabletz T. To differentiate or not - routes towards metastasis. Nat Rev Cancer. 2012;12(6):425-36.